NEW YORK (GenomeWeb) – In the wake of the first US Food and Drug Administration approval of a liquid biopsy test in June, stakeholders are grappling with the next steps in advancing additional clinical blood-based cancer tests under a changing landscape of regulatory oversight.
Representatives from liquid biopsy diagnostic firms, clinical researchers, FDA officials, payors, and drugmakers gathered on Tuesday for a joint FDA- and American Association for Cancer Research-sponsored workshop on the subject.